Evidence map›Paper›PMID 34055650›Full record

ArticleFrontiers in oncology2021

Case Report:

Junjie Fan, Hua Liang, Xing Zhang, Xingfa Chen, Xiaoyi Duan, Lei Li, Dalin He, Kaijie Wu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Case Report:Frontiers in oncology · 2022
    Article
  4. Article
  5. Solitary Penile Metastasis from Prostate Cancer onIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Junjie FanDepartment of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hua LiangDepartment of Pathology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xing ZhangDepartment of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xingfa ChenDepartment of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaoyi DuanDepartment of Radiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Lei LiDepartment of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Dalin HeDepartment of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kaijie WuDepartment of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNBaoji City Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastases from prostate cancer (PCa) to the penis are extremely rare, and few case reports exist in the literature. Because most patients usually present with multiple distant metastases at diagnosis, the prognosis is very poor. With the wide application of prostate-specific membrane antigen (PSMA) PET/CT, penile metastases may be detected at an early stage. Thus, questions regarding whether early diagnosis and precise treatment will equate to a survival advantage have recently been raised. In the present study, we reported 3 cases of penile metastasis from castration-resistant PCa. Moreover, a patient with asymptomatic penile metastases was diagnosed by

Indexed as

early diagnosispenile metastasesprostate cancerPSMA PET/CTsurvival advantage

Identifiers

PMID34055650
PMCPMC8155605
OpenAlexW3161466786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.